

## CORPORATE ACTION NOTICE

Amsterdam Market

No. CA170303DE

Issue Date:

3 March 2017

Effective Date:

To be announced

<b>Contracts:</b>	Single Stock Futures (COB & <i>Flex</i> )	SD6, <i>YSD</i>
-------------------	---	-----------------

**Company:** Stada Arzneimittel AG

**ISIN:** DE0007251803

**Corporate action:** Takeover

**Reference:** Press release of 23 February 2017, issued by Advent International Corporation.

**Details:** Advent International Corporation (“Advent”) submitted a legally binding offer to purchase all Stada Arzneimittel AG (“Stada”) shares for €58.00 per share. Stada shareholders remain entitled to receive the €0.72 per share dividend for the FY2016 under the offer, Advent expects the transaction to close after the dividend payment. (“the Offer”)

**Adjustments:** Provided that the Offer becomes effective, the contracts shall be de-listed with immediate effect and will be settled using the Fair Value method. In determining the Fair Value settlement prices, the following will apply:

**Futures:**

- **Dividends:** The dividend payments (as published by Markit Dividends) which are shown in the Attachment to this Notice will be used in determining the Fair Value settlement prices.
- **Interest rates:** Euribor interest rates shall be used in determining the Fair Value settlement prices.

This Notice is issued pursuant to the Corporate Actions Policy for the Euronext Derivatives Markets which is available on the [Euronext website](#). It requires the immediate attention of Members’ staff involved with the trading and settlement of equity products on these markets. Members should ensure that clients are made aware of the arrangements detailed in this Notice.

## CORPORATE ACTION NOTICE

For further information in relation to this Notice, Members should contact:

Euronext - EMS Corporate Actions	+31 (0) 20 721 9588	<a href="mailto:CorporateActionsTeam@euronext.com">mailto:CorporateActionsTeam@euronext.com</a> <a href="#">web: Euronext Derivatives Corporate Actions</a>
LCH - Derivatives Ops	+33 (0)1 7037 67 02	<a href="mailto:Derivatives.ops.fr@lch.com">mailto:Derivatives.ops.fr@lch.com</a>

The present notice and the contents thereof are only provided for information purposes in order to facilitate the fair, orderly and efficient functioning of the market and is not a recommendation to engage in investment activities. The contents of this notice are provided "as is" based on information provided to the market operator without representation or warranty of any kind. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this notice shall form the basis of any contract. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator.

The Euronext Markets comprise the markets operated by Euronext Amsterdam, Euronext Brussels, Euronext Lisbon, Euronext Paris and Euronext London, referred to respectively as the Amsterdam, Brussels, Lisbon, Paris and London markets, as relevant.

Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at <https://www.euronext.com/terms-use>.

© 2017 Euronext N.V. - All rights reserved.

Attachment to Corporate Action No. CA170303DE

**Stada Arzneimittel AG**

Corporate Action: **Takeover**

**Dividends:**

Dividend amount (€)	Ex-date
0.72	9 June 2017
0.78	8 June 2018
0.84	7 June 2019